ACHEMA Start-up Award Finalist: PRAMOMOLECULAR

Developing new active pharmaceutical ingredients is one thing. But how does the molecule get to the right place in the body? That requires transport systems. PRAMOMOLECULAR has developed and applied for a patent for a particularly simple system. With this technology therapeutic oligonucleotides will be transported into the target cell in order to silence disease-causing proteins in the lungs, heart or pancreas.

The micro- and molecular biologist has extensive experience in founding – she has been involved in founding seven start-up companies and has advised hundreds of companies on technology development and financing. "Germany has particularly good technological conditions for founding deep tech start-ups with disruption potential.” she states.  And founding is much more than “only” having a good idea: “We high-tech founders not only invest an incredible amount of time in technology development, market understanding, customer, and investor acquisition, but also in "storytelling" to clearly explain what we do and why this is important.” However, she would like to see even greater fundamental interest in these start-ups: “Because these problems, on which each of us deep-tech founders works far more than 5 days a week and 8 hours a day, are serious, the solutions we develop are also neither readily available nor easy. Unfortunately, there is often not enough patience and interest in our topics, neither in politics nor among investors or 'normal citizens'. And better basic scientific and technical knowledge would also make the dialogue – and perhaps even the funding of our start-ups – easier!"